Assertio Holdings WKN: A3CRAA ISIN: US04546C2052 Forum: Aktien User: Summer.76

Assertio Holdings: Recent Breakout To Lead To Sustained Gains https://seekingalpha.com/article/4500271-assertio-holdings-recent-breakout-leading-to-sustained-gains Summary • Company grows the top-line by 7% in Q4 due to strong performances from Indocin, Cambia & Zipsor. • Promising guidance eventually led to a breakout above the January highs. • We look at Assertio's profitability and valuation metrics to see if the breakout has merit. ...

Na nun ja nicht mehr 😉 Ja, sie war jetzt bemüht 🙃📈 Es gibt hierzu noch ein weiteres Forum. Möglicherweise liegt es daran.

ganz allein hier -Summer - gute performence die Monate - hat hier niemand aufm Schirm-

Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution Collaboration Eases Patient Access to Therapy https://www.globenewswire.com/news-release/2022/03/31/2413910/0/en/Assertio-Holdings-Inc-Partners-with-BlinkRx-to-Support-Healthcare-Providers-and-Patients-Utilizing-Otrexup-methotrexate-with-a-Unique-Patient-Access-Solution.html

Assertio Reports Fourth Quarter and Full Year 2021 Financial Results https://www.globenewswire.com/news-release/2022/03/09/2399962/0/en/Assertio-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html $32.2 Million Fourth Quarter Net Product Sales, a 7% Increase from Fourth Quarter 2020 and $109.4 Million Full Year Net Product Sales $17.8 Million Fourth Quarter Non-GAAP Adjusted EBITDA, a 118% Increase from Fourth Quarter 2020 and $48.8 Million Full Year Non-GAAP Adjusted EBITDA Provides 2022 Net Product Sales Guidance Range of $126.0 Million to $136.0 Million and 2022 Non-GAAP Adjusted EBITDA Guidance Range of $64.0 Million to $72.0 Million Completed Acquisition of Otrexup® (methotrexate)